Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Charles River
(NYSE:CRL)
Intraday
$239.43
-0.70
[-0.29%]
After-Hours
$239.43
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$239.43
-0.70
[-0.29%]
At close: Apr 24
$239.43
0
[0.00%]
After Hours: 4:03PM EDT
Get Report
Watch
Q1 2024 Earnings in 14 days from now on Thu May 9th, before the market open
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Charles River Stock (NYSE:CRL)
Charles River Stock (NYSE: CRL)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, April 23, 2024
Charles River shares are trading higher in possible sympathy with Danaher, which reported better-than-expected Q1 financial results.
Benzinga Newsdesk
-
1 day ago
Tuesday, April 16, 2024
Charles River Laboratories Launches Alternative Methods Advancement Project To Reduce Reliance On Animal Testing
Benzinga Newsdesk
-
Apr 16, 2024, 8:04AM
Thursday, April 04, 2024
Charles River To Perform Plasmid Production For Ship Of Theseus
Benzinga Newsdesk
-
Apr 4, 2024, 8:09AM
Thursday, March 21, 2024
Charles River Announces Extension Of Gene Therapy Manufacturing Alliance With NUS Yong Loo Lin School Of Medicine
Benzinga Newsdesk
-
Mar 21, 2024, 8:04AM
Monday, March 18, 2024
Evaluating Charles River: Insights From 7 Financial Analysts
Benzinga Insights
-
Mar 18, 2024, 2:01PM
Argus Research Maintains Buy on Charles River, Raises Price Target to $290
Benzinga Newsdesk
-
Mar 18, 2024, 10:12AM
Thursday, March 14, 2024
Charles River And Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
Happy Mohamed
-
Mar 14, 2024, 8:17AM
Monday, March 04, 2024
Durect Corporation Has Entered Into A Co-marketing And Collaboration Agreement With Charles River Laboratories For The Alzet Osmotic Pumps Portfolio And Associated Product Line In The US And Canada
Benzinga Newsdesk
-
Mar 4, 2024, 7:02AM
Thursday, February 29, 2024
Wheeler Bio Taps Charles River to Offer Portable CMC to Discovery Clients to Accelerate Their Journey to First-in-Human Use
Benzinga Newsdesk
-
Feb 29, 2024, 2:28AM
Wednesday, February 21, 2024
Charles River And Wheeler Bio Complete Agreement To Accelerate The Journey From Discovery And CMC Development To Manufacturing
Benzinga Newsdesk
-
Feb 21, 2024, 8:28AM
Tuesday, February 20, 2024
Charles River Collaborates With Pluristyx, Expanding Its Portfolio Of Human Pluripotent Stem Cells
Benzinga Newsdesk
-
Feb 20, 2024, 8:45AM
Thursday, February 15, 2024
Forecasting The Future: 4 Analyst Projections For Charles River
Benzinga Insights
-
Feb 15, 2024, 11:01AM
Guggenheim Downgrades Charles River to Neutral
Benzinga Newsdesk
-
Feb 15, 2024, 8:02AM
Wednesday, February 14, 2024
Stocks Rebound As Investor Focus Shifts To Earnings, Bitcoin Tops $1 Trillion Value: What's Driving Markets Wednesday?
Piero Cingari
-
Feb 14, 2024, 1:51PM
Charles River Laboratories Stock Surges On Upbeat Annual Outlook, But This Analyst Is Concerned
Vandana Singh
-
Feb 14, 2024, 1:40PM
Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
-
Feb 14, 2024, 1:18PM
Charles River Laboratories International Posts Upbeat Results, Joins Robinhood, Zillow, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor
-
Feb 14, 2024, 10:36AM
Charles River Laboratories shares are trading higher after the company reported better-than-expected Q4 results and issued guidance above estimates.
Benzinga Newsdesk
-
Feb 14, 2024, 10:15AM
Charles River Forecasts 2024 Adjusted EPS Of $10.90–$11.40 Versus Consensus Of $10.87
Benzinga Newsdesk
-
Feb 14, 2024, 7:08AM
Charles River Expects 2024 Revenue Growth Of 1.0%–4.0% On A Reported Basis, With Organic Growth Of 0.0%–3.0%
Benzinga Newsdesk
-
Feb 14, 2024, 7:06AM
Charles River Q4 Adjusted EPS $2.46 Beats $2.40 Estimate, Sales $1.01B Beat $991.25M Estimate
Benzinga Newsdesk
-
Feb 14, 2024, 7:03AM
Earnings Scheduled For February 14, 2024
Benzinga Insights
-
Feb 14, 2024, 4:48AM
Thursday, February 01, 2024
James C Foster At Charles River Executes Options Exercise, Realizing $1.25M
Benzinga Insights
-
Feb 1, 2024, 10:01AM
Monday, January 29, 2024
Charles River Introduces The First Rapid Animal-Free Bacterial Endotoxin Test
Benzinga Newsdesk
-
Jan 29, 2024, 8:15AM
Wednesday, December 20, 2023
JP Morgan Maintains Overweight on Charles River, Raises Price Target to $270
Benzinga Newsdesk
-
Dec 20, 2023, 2:56PM
Monday, December 18, 2023
Charles River Laboratories International Announced Milestone In Its Strategic Collaboration With Vertex Pharmaceuticals To Manufacture CASGEVY
Benzinga Newsdesk
-
Dec 18, 2023, 8:03AM
Tuesday, December 12, 2023
Charles River Finalizes Agreement With CELLphenomics, Expanding 3D In Vitro Services For Cancer Therapy Drug Screening
Benzinga Newsdesk
-
Dec 12, 2023, 8:11AM
Monday, December 11, 2023
9 Analysts Have This to Say About Charles River
Benzinga Insights
-
Dec 11, 2023, 11:00AM
Citigroup Maintains Neutral on Charles River, Raises Price Target to $215
Benzinga Newsdesk
-
Dec 11, 2023, 7:03AM
Tuesday, November 28, 2023
Charles River And Genetic Cures For Kids Announce Gene Therapy Manufacturing Collaboration
Benzinga Newsdesk
-
Nov 28, 2023, 8:12AM
Wednesday, November 15, 2023
Charles River Chairman Makes $1.00M Stock Purchase
Benzinga Insights
-
Nov 15, 2023, 10:02AM
Monday, November 13, 2023
Charles River And Aitia Enter Strategic Agreement To Utilize Logica In Discovery Programs for Neurodegenerative Diseases And Oncology; Aitia To Deploy Logica Across Their Portfolio Of Drug Targets
Benzinga Newsdesk
-
Nov 13, 2023, 9:08AM
Friday, November 10, 2023
Expert Ratings for Charles River
Benzinga Insights
-
Nov 10, 2023, 10:00AM
Morgan Stanley Maintains Equal-Weight on Charles River, Lowers Price Target to $205
Benzinga Newsdesk
-
Nov 10, 2023, 8:54AM
Thursday, November 09, 2023
UBS Maintains Buy on Charles River, Lowers Price Target to $215
Benzinga Newsdesk
-
Nov 9, 2023, 2:50PM
Wednesday, November 08, 2023
Charles River Labs Q3 Revenue Jumps 4% Despite Softer Client Spending, Narrows Outlook
Vandana Singh
-
Nov 8, 2023, 11:23AM
Charles River Narrows FY2023 Adj EPS Guidance from $10.30-$10.90 to $10.50 - $10.70 vs. $10.56 Est;
Benzinga Newsdesk
-
Nov 8, 2023, 7:20AM
Charles River Lowers FY2023 GAAP EPS Guidance from to $7.60-8.20 to $7.30 - $7.50
Benzinga Newsdesk
-
Nov 8, 2023, 7:18AM
Charles River Q3 Adj. EPS $2.72 Beats $2.37 Estimate, Sales $1.03B Beat $1.00B Estimate
Benzinga Newsdesk
-
Nov 8, 2023, 7:07AM
Earnings Scheduled For November 8, 2023
Benzinga Insights
-
Nov 8, 2023, 4:21AM
Wednesday, October 25, 2023
Shares of healthcare equipment and tools stocks are trading lower in sympathy with Thermo Fisher and Danaher.
Benzinga Newsdesk
-
Oct 25, 2023, 3:03PM
Tuesday, October 24, 2023
8 Analysts Have This to Say About Charles River
Benzinga Insights
-
Oct 24, 2023, 10:00AM
Morgan Stanley Maintains Equal-Weight on Charles River, Lowers Price Target to $220
Benzinga Newsdesk
-
Oct 24, 2023, 8:23AM
Monday, October 16, 2023
Charles River Laboratories Provides Access To Relevant, Well-Characterized Pediatric PDX Collection For Oncology Research
Benzinga Newsdesk
-
Oct 16, 2023, 8:34AM
Tuesday, September 26, 2023
Charles River Unveils Lentivation Platform To Expedite LVV-Based Gene Therapy Manufacturing
Benzinga Newsdesk
-
Sep 26, 2023, 8:15AM
Monday, September 25, 2023
TD Cowen Maintains Market Perform on Charles River, Lowers Price Target to $209
Benzinga Newsdesk
-
Sep 25, 2023, 11:18AM
Friday, September 22, 2023
Baird Maintains Outperform on Charles River, Lowers Price Target to $256
Benzinga Newsdesk
-
Sep 22, 2023, 12:44PM
Guggenheim Maintains Buy on Charles River, Lowers Price Target to $225
Benzinga Newsdesk
-
Sep 22, 2023, 11:40AM
Wells Fargo Maintains Overweight on Charles River, Lowers Price Target to $275
Benzinga Newsdesk
-
Sep 22, 2023, 9:15AM
Thursday, September 21, 2023
Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
Sep 21, 2023, 1:16PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch